OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.570
+0.110 (7.53%)
Aug 20, 2026, 4:00 PM EDT - Market closed
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,873,916
Market Cap
69.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| PMV Pharmaceuticals | 54 |
| Cardiff Oncology | 31 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| ImageneBio | 18 |
OSTX News
- 3 days ago - OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates - Newsfile Corp
- 6 days ago - OS Therapies Quarterly report: Q2 2026 - Filings
- 7 days ago - OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 21 days ago - OS Therapies terminates At Market Issuance Sales Agreement - TheFly
- 27 days ago - OS Therapies Proxy statement: Proxy filing - Filings
- 27 days ago - OS Therapies Proxy statement: Proxy filing - Filings
- 6 weeks ago - OS Therapies initiated with a Buy at Roth Capital - TheFly
- 6 weeks ago - OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program - Newsfile Corp